Betamethasone sodium phosphate | CAS#151-73-5 | glucocorticoid steroid

MedKoo Cat#: 598938 | Name: Betamethasone sodium phosphate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Betamethasone sodium phosphate is a Betamethasone derivative. It is a glucocorticoid steroid with anti-inflammatory and immunosuppressive properties which can be used in treatment of asthma and itching.

Chemical Structure

Betamethasone sodium phosphate

CAS#151-73-5 (sodium phosphate)

Theoretical Analysis

MedKoo Cat#: 598938

Name: Betamethasone sodium phosphate

CAS#: 151-73-5 (sodium phosphate)

Chemical Formula: C22H28FNa2O8P

Exact Mass: 0.0000

Molecular Weight: 516.40

Elemental Analysis: C, 51.17; H, 5.47; F, 3.68; Na, 8.90; O, 24.78; P, 6.00

Price and Availability

Size	Price	Availability
500mg	USD 150.00	Ready to ship
1g	USD 250.00	Ready to ship
2g	USD 425.00	Ready to ship
5g	USD 750.00	Ready to ship
10g	USD 1,250.00	Ready to ship
20g	USD 2,050.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

378-44-9 (free acid) 5534-05-4 (acibutate) 987-24-6 (acetate) 5593-20-4 (dipropionate) 151-73-5 (sodium phosphate) 2152-44-5 (valerate) 22298-29-9 (benzoate)

Synonym

Betamethasone sodium phosphate; NSC 90616; NSC-90616; NSC90616; Bentelan; BDP; Celestone;

IUPAC/Chemical Name

sodium 2-((8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl phosphate

InChi Key

PLCQGRYPOISRTQ-LWCNAHDDSA-L

InChi Code

InChI=1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15-,16-,17-,19-,20-,21-,22-;;/m0../s1

SMILES Code

C[C@@]12[C@](C(COP([O-])([O-])=O)=O)(O)[C@@H](C)C[C@@]1([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C2)=O.[Na+].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#A20T12K18

QC Data

View QC data: current batch, Lot#A20T12K18

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Betamethasone sodium phosphate is a glucocorticoid steroid with anti-inflammatory and immunosuppressive properties.

In vitro activity:

TBD

In vivo activity:

To evaluate anti-inflammatory and antiallergic activities in vivo, betamethasone phosphate was tested in the carrageenan-induced conjunctivitis model and allergic conjunctivitis model in rats. When given as eyedrops, betamethasone phosphate had an inhibitory effect on edema weight in the rat carrageenan-induced conjunctivitis model. Reference: J Ocul Pharmacol Ther. 2011 Aug;27(4):353-60. https://www.liebertpub.com/doi/10.1089/jop.2010.0177?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

	Solvent	mg/mL	mM
Solubility
	PBS (pH 7.2)	10.0	19.36
	Water	30.0	58.09

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 516.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Kato M, Hagiwara Y, Oda T, Imamura-Takai M, Aono H, Nakamura M. Beneficial pharmacological effects of selective glucocorticoid receptor agonist in external eye diseases. J Ocul Pharmacol Ther. 2011 Aug;27(4):353-60. doi: 10.1089/jop.2010.0177. Epub 2011 May 16. PMID: 21574866.

In vitro protocol:

TBD

In vivo protocol:

1: Ghasemnejad M, Ahmadi E, Mohamadnia Z, Doustgani A, Hashemikia S. Functionalized silica nanoparticles as a carrier for Betamethasone Sodium Phosphate: Drug release study and statistical optimization of drug loading by response surface method. Mater Sci Eng C Mater Biol Appl. 2015 Nov 1;56:223-32. doi: 10.1016/j.msec.2015.06.012. Epub 2015 Jun 18. PubMed PMID: 26249584. 2: Simon A, de Almeida Borges VR, Cabral LM, de Sousa VP. Development and validation of a discriminative dissolution test for betamethasone sodium phosphate and betamethasone dipropionate intramuscular injectable suspension. AAPS PharmSciTech. 2013 Mar;14(1):425-34. doi: 10.1208/s12249-012-9920-2. Epub 2013 Feb 1. PubMed PMID: 23371786; PubMed Central PMCID: PMC3581667. 3: Menendez MI, Phelps MA, Bertone AL. Pharmacokinetics of intra-articular betamethasone sodium phosphate and betamethasone acetate and endogenous hydrocortisone suppression in exercising horses. J Vet Pharmacol Ther. 2016 Feb;39(1):22-6. doi: 10.1111/jvp.12229. Epub 2015 Apr 3. PubMed PMID: 25847081. 4: Habib G, Artul S, Chernin M, Hakim G, Jabbour A. The effect of intra-articular injection of betamethasone acetate/betamethasone sodium phosphate at the knee joint on the hypothalamic-pituitary-adrenal axis: a case-controlled study. J Investig Med. 2013 Oct;61(7):1104-7. doi: 10.2310/JIM.0b013e3182a67871. PubMed PMID: 24013525. 5: Chen MY, Tang YJ, Wang YC, Wang CZ, Yuan CS, Chen Y, Tan ZR, Huang WH, Zhou HH. Quantitative determination of betamethasone sodium phosphate and betamethasone dipropionate in human plasma by UPLC-MS/MS and a bioequivalence study. Anal Methods. 2016 May 7;8(17):3550-3563. Epub 2016 Mar 29. PubMed PMID: 27695531; PubMed Central PMCID: PMC5042352. 6: Salem II, Najib NM. Pharmacokinetics of betamethasone after single-dose intramuscular administration of betamethasone phosphate and betamethasone acetate to healthy subjects. Clin Ther. 2012 Jan;34(1):214-20. doi: 10.1016/j.clinthera.2011.11.022. Epub 2011 Dec 9. PubMed PMID: 22154197. 7: Iwata M, Koide T, Maekawa K, Saito H, Tanimoto T, Okada S. [Betamethasone Sodium Phosphate Reference Standard (Control 001) of National Institute of Health Sciences]. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2001;(119):78-81. Japanese. PubMed PMID: 11915291. 8: Habib G, Artul S, Hakim G. Annoying Hiccups following Intra-Articular Corticosteroid Injection of Betamethasone Acetate/Betamethasone Sodium Phosphate at the Knee Joint. Case Rep Rheumatol. 2013;2013:829620. doi: 10.1155/2013/829620. Epub 2013 Mar 14. PubMed PMID: 23573452; PubMed Central PMCID: PMC3612444. 9: Kreienbaum MA. Stability of betamethasone sodium phosphate, hydrocortisone sodium phosphate, and prednisolone sodium phosphate injections submitted by U.S. hospitals. Am J Hosp Pharm. 1986 Jul;43(7):1747-50. PubMed PMID: 3752113. 10: Okada S, Hiroshige R, Tanaka M, Murai M, Kimura T. [Betamethasone Sodium Phosphate Reference Standard (Control 881) of National Institute of Hygienic Sciences]. Eisei Shikenjo Hokoku. 1990;(108):141-4. Japanese. PubMed PMID: 1364345. 11: Patel RS, Shaw SR, Wallace AM, McGarry GW. Efficacy and systemic tolerability of mometasone furoate and betamethasone sodium phosphate. J Laryngol Otol. 2004 Nov;118(11):866-71. PubMed PMID: 15638973. 12: Betamethasone sodium phosphate. Nurs Times. 2004 Dec 7-13;100(49):43. Review. PubMed PMID: 15630973. 13: He C, Fan H, Tan J, Zou J, Zhu Y, Yang K, Hu Q. Pharmacokinetics of betamethasone and betamethasone 17-monopropionate in Chinese healthy volunteers after intramuscular injection of betamethasone phosphate/betamethasone dipropionate. Arzneimittelforschung. 2011;61(7):417-20. doi: 10.1055/s-0031-1296220. PubMed PMID: 21899210. 14: Kemp MW, Saito M, Usuda H, Molloy TJ, Miura Y, Sato S, Watanabe S, Clarke M, Fossler M, Scmidt A, Kallapur SG, Kramer BW, Newnham JP, Jobe AH. Maternofetal pharmacokinetics and fetal lung responses in chronically catheterized sheep receiving constant, low-dose infusions of betamethasone phosphate. Am J Obstet Gynecol. 2016 Dec;215(6):775.e1-775.e12. doi: 10.1016/j.ajog.2016.08.017. Epub 2016 Aug 20. PubMed PMID: 27555319. 15: Li M, Wang X, Chen B, Chan TM, Rustum A. Forced degradation of betamethasone sodium phosphate under solid state: Formation, characterization, and mechanistic study of all four 17,20-diastereomers of betamethasone 17-deoxy-20-hydroxy-21-oic acid. J Pharm Sci. 2009 Mar;98(3):894-904. doi: 10.1002/jps.21477. PubMed PMID: 18623204. 16: Dołowy M, Pyka A. EVALUATION OF LIPOPHILIC PROPERTIES OF BETAMETHASONE AND RELATED COMPOUNDS. Acta Pol Pharm. 2015 Jul-Aug;72(4):671-81. PubMed PMID: 26647623. 17: Lederer V. Betamethasone sodium phosphate injection: high-dose regimen in septic shock. Clin Ther. 1984;6(5):719-26. PubMed PMID: 6383616. 18: Watson DG, McGhee CN, Midgley JM, Dutton GN, Noble MJ. Penetration of topically applied betamethasone sodium phosphate into human aqueous humour. Eye (Lond). 1990;4 ( Pt 4):603-6. PubMed PMID: 2226991. 19: Samtani MN, Schwab M, Nathanielsz PW, Jusko WJ. Stabilization and HPLC analysis of betamethasone sodium phosphate in plasma. J Pharm Sci. 2004 Mar;93(3):726-32. PubMed PMID: 14762910. 20: Teranishi S, Chikama T, Nishida T. [Effect of preservative-free betamethasone sodium phosphate eyedrops on the development of corneal epithelial disorders after penetrating keratoplasty]. Nippon Ganka Gakkai Zasshi. 2009 Feb;113(2):101-6. Japanese. PubMed PMID: 19260528.